BeOne and Revolution Medicines Team Up on RAS-Driven Cancer Combinations

BeOne Medicines, formerly BeiGene, and Revolution Medicines are joining forces to test combination therapies against cancers driven by mutations in the notoriously hard-to-drug RAS gene.

Announced August 11, 2026, the deal has two parts: joint clinical studies combining the companies’ drugs in RAS-addicted cancers, and a regional rights agreement giving BeOne exclusive development and commercialisation rights in select Asian markets. Revolution keeps everything else, including Japan and South Korea. BeOne will fund and run a global Phase 3 registrational trial.

What RAS(ON) inhibitors do

Revolution brings daraxonrasib, zoldonrasib, elironrasib and RMC-5127 — a class designed to hit the active form of RAS.

That distinction is the technical core. RAS proteins cycle between an inactive state bound to one nucleotide and an active state bound to another, and the active form is what drives growth signalling.

The first successful RAS drugs targeted the inactive state, trapping proteins there as they cycled. That works and depends on the protein spending time inactive — and mutations differ in how much they do. Some RAS mutations lock the protein active almost permanently, rendering inactive-state inhibitors ineffective.

Targeting the active form directly addresses those mutations, which is why a RAS(ON) approach covers substantially more of the RAS-mutant population than the first generation did.

Why combinations are the strategy

Combining a RAS drug with complementary agents is a leading strategy to boost responses and fend off resistance, and the reasoning comes from experience with the first-generation drugs.

Those produced responses that were frequently shorter than the initial data suggested, because tumours escaped through several routes — new mutations at the binding site, target amplification, and reactivation of the same pathway through parallel signals.

Pathway redundancy is the underlying problem. RAS sits within a network with alternative routes to the same downstream outcome, so blocking one node reliably selects for tumours using another.

Combination therapy attacks that directly — block RAS and simultaneously block the escape route.

What BeOne contributes

BeOne pairs the RAS inhibitors with assets from its own pipeline, including the PRMT5 inhibitor BGB-58067 and a trispecific antibody, BG-T187.

PRMT5 is a mechanistically interesting partner. It is an enzyme involved in the regulation of gene expression and RNA processing, and it has attracted interest because tumours with a particular common deletion become selectively dependent on it — a synthetic lethal relationship. Pairing it with RAS inhibition targets two distinct vulnerabilities rather than the same pathway twice.

A trispecific antibody adds an immune-directed mechanism, which is different again — combining targeted inhibition with immune engagement rather than layering two targeted agents.

Why the deal structure makes sense for both

The arrangement solves different problems for each party.

For Revolution, it extends the RAS franchise into Asia while a partner shoulders trial costs. Running a global Phase 3 is expensive, and a company with multiple assets advancing simultaneously has finite capital — having BeOne fund and operate the trial preserves resources for the programmes Revolution retains fully.

For BeOne, it provides access to a validated class the company did not develop, in markets where it has commercial infrastructure. “This collaboration…gives BeOne the opportunity to evaluate combinations between assets from our oncology pipeline and four promising RAS(ON) inhibitors,” said CEO John Oyler.

Financial terms were not disclosed, though the deal includes development milestones and tiered royalties to Revolution.

Why Japan and South Korea were carved out

Revolution retaining those two markets while granting other Asian rights is a deliberate distinction, and it reflects their commercial character.

Japan and South Korea are large, high-value pharmaceutical markets with sophisticated regulatory systems and pricing that supports premium oncology products. They behave more like Western markets than like the rest of the region commercially, and a company retaining global rights outside a partnership would want to keep them.

The scale of the opportunity

RAS mutations are among the most common in cancer, driving many lung, colorectal and pancreatic tumours, and the target long resisted drugging entirely.

What synthetic lethality means and why it matters here

The PRMT5 component of this partnership rests on a concept worth explaining, because it represents a distinct approach to cancer targeting.

Synthetic lethality describes a relationship where losing either of two genes is survivable but losing both is fatal. The therapeutic application follows directly: if a cancer has already lost one gene through mutation or deletion, a drug inhibiting its partner kills the tumour while leaving normal cells — which retain both — largely unharmed.

The best-established example is PARP inhibition in cancers with defective DNA repair, where tumours carrying certain inherited mutations are selectively vulnerable to blocking an alternative repair pathway.

PRMT5 fits the same pattern. A commonly deleted region of the genome in many cancers removes a gene whose loss makes cells dependent on PRMT5 — so a PRMT5 inhibitor should kill those tumours specifically. Combining that with RAS inhibition targets two genuinely independent vulnerabilities, which is a stronger rationale than combining two drugs that both attack the same pathway.

A class of drugs that works against the active form, paired with agents addressing the routes tumours use to escape, is the logical next stage after demonstrating that RAS can be drugged at all — and the combination question is where the durability of the whole approach will be settled. Business news, not investment advice.